Developer docs
API playgroundTry for free, no card

Search company profiles

Sanoculis

Full company profile

uuid000as38

Namestring
Sanoculis
Legal namestring
Sanoculis LTD.
Websiteurl
sanoculis.com
Company typeenum
Private
Founded yearint
2012
Descriptiontext

Sanoculis Ltd. is an Israeli medical device company founded in 2012 and headquartered in Kiryat Ono, Israel. The company develops proprietary, stent-free, minimally invasive surgical platforms for the treatment of glaucoma: MINT® (Minimally Invasive Nasal Trabeculostomy), which uses a semi-automated mechanical trephination with a 0.14mm cutting edge to create five drainage pathways in the trabecular meshwork, and MIMS® (Minimally Invasive Micro Sclerostomy), a stentless procedure that creates a sclerostomy channel for continuous aqueous drainage. Both platforms are designed for standalone use or in combination with cataract surgery (phacoemulsification), targeting ophthalmologists and glaucoma surgeons in hospitals and eye surgery centers.

The technology stack is mechanical and procedural rather than digital: the MINT® device is positioned on the trabecular meshwork via a gonioscope and operated via a foot pedal, while the MIMS® system includes a touchscreen-controlled surgical console with a handheld cutting tool. MIMS® is CE marked under MDD 93/42/EEC and MINT® is CE marked under MDR 2017/745, both registered trademarks of Sanoculis. Clinical data show 97.2% qualified success at two years for MINT® standalone (FDA definition, N=35/36), 36% IOP reduction with 50% medication reduction at two years, and for MIMS®, 38% IOP reduction and 85% medication reduction at 12 months with zero major intra/post-operative complications (N=120) and a procedure duration of 2:03 ± 0:43 minutes.

Sanoculis generates revenue through hardware sales of MINT® and MIMS® devices to healthcare providers, with distribution executed through exclusive channel partners: Bausch + Lomb holds exclusive European distribution rights for MIMS® (as of the January 2023 Series C round), and Skymed distributes Sanoculis products in Israel. Pricing is quote-based and not publicly disclosed. The company is venture-backed (Series C, January 2023, with Eckuity and Bausch + Lomb as investors), maintains a Medical Advisory Board of globally recognized glaucoma surgeons, and shows operational footprints in Israel, Europe, India, and signals of early US expansion via a VP of Clinical Affairs US.

Short descriptiontext

Sanoculis is an Israeli medical device company that develops proprietary stent-free, minimally invasive surgical platforms — MINT® and MIMS® — for the treatment of open-angle glaucoma, sold to ophthalmologists and glaucoma surgeons through exclusive distributors.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersKiryat Gat, Israel
HQ citystring
Kiryat Gat
HQ countrystring
Israel
HQ regionstring
Middle East
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
minimally invasive glaucoma surgery, ophthalmic medical devices, trabeculostomy devices, interventional glaucoma, intraocular pressure reduction
Industry1 code
SECONDARYHLAHAJAI
Glaucoma Diagnostics & Surgical Devices (Tonometry, Gonioscopy, MIGS, Drainage Implants, Laser Trabeculoplasty)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
NAICS code1 code
  • Surgical Appliance and Supplies Manufacturing339113
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Ophthalmic Medical Devices
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Device Sales
TypeHardware Sales
Description

Sanoculis generates revenue through the sale of its proprietary MINT® and MIMS® surgical devices and related surgical systems. As a medical device company, revenue is derived from hardware/device sales to healthcare providers, hospitals, and eye surgery centers. Distribution is primarily through exclusive channel partners in international markets.

sanoculis.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Supply Chain, Marketing or Sales, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1MINT®
Description

Minimally Invasive Nasal Trabeculostomy - A CE marked device under MDR 2017/745 for glaucoma treatment. Creates five drainage pathways directly within the trabecular meshwork using a mechanical semi-automated trephination with a cutting edge diameter of 0.14mm.

sanoculis.com
+1 more record
Core offering1 text field

Sanoculis develops and sells two proprietary, stent-free, minimally invasive ophthalmic surgical devices for glaucoma treatment: MINT® (Minimally Invasive Nasal Trabeculostomy) and MIMS® (Minimally Invasive Micro Sclerostomy). Both devices are sold to hospitals, eye surgery centers, and ophthalmologists for standalone use or in combination with cataract surgery, and are CE marked for the European market.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • MINT® 2-year standalone: 97.2% qualified success rate (FDA definition: ≥20% IOP reduction without increasing meds, N=35/36)
+3 more records
Product overview1 text field

Sanoculis is a medical device company specializing in ophthalmic technology with two core stentless, minimally invasive glaucoma treatment products: MINT® (Minimally Invasive Nasal Trabeculostomy), which creates trabecular meshwork drainage pathways via a semi-automated trephination device, and MIMS® (Minimally Invasive Micro Sclerostomy), which creates a sclerostomy channel for IOP reduction. Both devices are designed for standalone use or combination with cataract surgery, offering stent-free alternatives to traditional filtration surgery with lower complication rates.

Product and service2 records
1MINT® (Minimally Invasive Nasal Trabeculostomy)
CategoryOphthalmic Surgical Devices / Glaucoma Surgery
Description

MINT® is a stent-free, minimally invasive ophthalmic surgical device that creates five drainage pathways directly within the trabecular meshwork using a proprietary mechanical semi-automated trephination with a 0.14mm cutting edge diameter. It is intended for ophthalmologists and glaucoma surgeons to lower intraocular pressure in open-angle glaucoma patients, either as a standalone procedure or combined with cataract surgery.

2MIMS® (Minimally Invasive Micro Sclerostomy)
CategoryOphthalmic Surgical Devices / Glaucoma Surgery
Description

MIMS® is a stentless ophthalmic surgical device and system that creates a sclerostomy by inserting a cutting tool into the sclera to remove a small channel of tissue, allowing continuous drainage of fluid to reduce intraocular pressure. The accompanying surgical system features a central control touchscreen and a foot pedal for precise handheld cutting tool movement. It is sold to hospitals and ophthalmologists for standalone glaucoma surgery or combined with cataract surgery.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierFlagshipTypeChannel Partner/ Reseller/ DistributorAnnounced on2023-01-25
Description

Bausch + Lomb invested in Sanoculis during its Series C funding round (January 2023) and entered an exclusive European distribution agreement for Sanoculis' MIMS® glaucoma treatment device. This is a significant strategic partnership providing Sanoculis with broad market access across Europe through a major ophthalmic surgical company. Bausch + Lomb Surgical EMEA is based at 416 Rue Samuel Morse, Le Millenaire 2, BP 1174, 34009 Montpellier, France.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Skymed is the Israeli distributor for Sanoculis products including MIMS® and MINT® devices. Located at Hafrat 2, Yavne, Israel 8122702. Contact: 072-2555-240, service@skymed.co.il. This distribution partnership enables Sanoculis to reach ophthalmologists and eye surgery centers throughout Israel.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Sight Sciences markets the OMNI Surgical System, an ab-interno MIGS device for glaucoma that, like MINT and MIMS, targets interventional glaucoma and combination cataract workflows. Comparable in stage and MIGS focus.

TypeDirect peer
Description

Glaukos is the pioneer and market leader in MIGS, with iStent and iStent inject devices used in standalone and combination cataract-MIGS procedures. Directly competes with Sanoculis' MINT and MIMS in the same ophthalmic surgical channels and target surgeon base.

TypeDirect peer
Description

Nova Eye Medical sells iTrack, a canaloplasty MIGS device for glaucoma. Targets the same MIGS / interventional glaucoma surgeon base with an ab-interno approach, making it a directly comparable peer.

TypeEmerging player
Description

iSTAR Medical develops MINIject, a suprachoroidal MIGS implant. Competes in the same MIGS category with a differentiated mechanism, addressing the same glaucoma patient population and surgeon base as Sanoculis.

TypeRegional player
Description

MicroSurgical Technology (MST) manufactures micro-incision surgical instruments used in ophthalmic surgery, including glaucoma procedures. Comparable as a peer in surgical glaucoma instrumentation, with primary presence in the US.

TypeBroad incumbent
Description

Alcon is a global ophthalmic surgical incumbent with the Hydrus Microstent (acquired via Ivantis) and a broad cataract surgery portfolio. Overlaps directly with Sanoculis in MIGS and combination cataract-glaucoma procedures, but competes from a much larger installed base and sales footprint.

TypeEmerging player
Description

Belkin Vision develops the Eagle Direct Selective Laser Trabeculoplasty device, a non-incisional MIGS alternative. Targets the same interventional glaucoma surgeon base with an emerging, non-implant approach.

TypeBroad incumbent
Description

Bausch + Lomb is both a strategic partner (Series C investor and exclusive European distributor of MIMS) and a broad ophthalmic incumbent with surgical, pharmaceutical, and vision care portfolios. Comparable as a wide-line ophthalmic surgical competitor to Sanoculis' stent-free MIGS offering.

TypeDirect peer
Description

New World Medical markets the Kahook Dual Blade, an ab-interno goniotomy device used in standalone and combination cataract-MIGS procedures. Directly competes with Sanoculis in the surgical trabeculostomy space.

TypeDirect peer
Description

Ellex (now part of Lumibird Medical) offers laser-based MIGS solutions, including laser trabeculoplasty devices. Targets the same MIGS / interventional glaucoma surgeon base as Sanoculis, though with a different mechanism.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Sanoculis

Ophthalmic Medical Devicessanoculis.com

Sanoculis is an Israeli medical device company that develops proprietary stent-free, minimally invasive surgical platforms — MINT® and MIMS® — for the treatment of open-angle glaucoma, sold to ophthalmologists and glaucoma surgeons through exclusive distributors.

What Sanoculis does

Sanoculis Ltd. is an Israeli medical device company founded in 2012 and headquartered in Kiryat Ono, Israel. The company develops proprietary, stent-free, minimally invasive surgical platforms for the treatment of glaucoma: MINT® (Minimally Invasive Nasal Trabeculostomy), which uses a semi-automated mechanical trephination with a 0.14mm cutting edge to create five drainage pathways in the trabecular meshwork, and MIMS® (Minimally Invasive Micro Sclerostomy), a stentless procedure that creates a sclerostomy channel for continuous aqueous drainage. Both platforms are designed for standalone use or in combination with cataract surgery (phacoemulsification), targeting ophthalmologists and glaucoma surgeons in hospitals and eye surgery centers.

The technology stack is mechanical and procedural rather than digital: the MINT® device is positioned on the trabecular meshwork via a gonioscope and operated via a foot pedal, while the MIMS® system includes a touchscreen-controlled surgical console with a handheld cutting tool. MIMS® is CE marked under MDD 93/42/EEC and MINT® is CE marked under MDR 2017/745, both registered trademarks of Sanoculis. Clinical data show 97.2% qualified success at two years for MINT® standalone (FDA definition, N=35/36), 36% IOP reduction with 50% medication reduction at two years, and for MIMS®, 38% IOP reduction and 85% medication reduction at 12 months with zero major intra/post-operative complications (N=120) and a procedure duration of 2:03 ± 0:43 minutes.

Sanoculis generates revenue through hardware sales of MINT® and MIMS® devices to healthcare providers, with distribution executed through exclusive channel partners: Bausch + Lomb holds exclusive European distribution rights for MIMS® (as of the January 2023 Series C round), and Skymed distributes Sanoculis products in Israel. Pricing is quote-based and not publicly disclosed. The company is venture-backed (Series C, January 2023, with Eckuity and Bausch + Lomb as investors), maintains a Medical Advisory Board of globally recognized glaucoma surgeons, and shows operational footprints in Israel, Europe, India, and signals of early US expansion via a VP of Clinical Affairs US.

Sanoculis firmographics

Firmographics
Name
Sanoculis
Legal name
Sanoculis LTD.
Website
https://sanoculis.com
Company type
Private
Founded year
2012
Operating status
Operating
Headcount range
1–10 employees
Short description
Sanoculis is an Israeli medical device company that develops proprietary stent-free, minimally invasive surgical platforms — MINT® and MIMS® — for the treatment of open-angle glaucoma, sold to ophthalmologists and glaucoma surgeons through exclusive distributors.
Ownership category
akta.pro rank

Where Sanoculis is headquartered

Location

Headquarters

HQ city
Kiryat Gat
HQ country
Israel
HQ region
Middle East

Offices1 record

Markets served

Sanoculis business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Marketing or Sales, Personnel, Operations

Revenue model

  1. Medical Device Sales: Sanoculis generates revenue through the sale of its proprietary MINT® and MIMS® surgical devices and related surgical systems. As a medical device company, revenue is derived from hardware/device sales to healthcare providers, hospitals, and eye surgery centers. Distribution is primarily through exclusive channel partners in international markets.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Sanoculis product offering

Product offering

Core offering

Sanoculis develops and sells two proprietary, stent-free, minimally invasive ophthalmic surgical devices for glaucoma treatment: MINT® (Minimally Invasive Nasal Trabeculostomy) and MIMS® (Minimally Invasive Micro Sclerostomy). Both devices are sold to hospitals, eye surgery centers, and ophthalmologists for standalone use or in combination with cataract surgery, and are CE marked for the European market.

Product overview

Sanoculis is a medical device company specializing in ophthalmic technology with two core stentless, minimally invasive glaucoma treatment products: MINT® (Minimally Invasive Nasal Trabeculostomy), which creates trabecular meshwork drainage pathways via a semi-automated trephination device, and MIMS® (Minimally Invasive Micro Sclerostomy), which creates a sclerostomy channel for IOP reduction. Both devices are designed for standalone use or combination with cataract surgery, offering stent-free alternatives to traditional filtration surgery with lower complication rates.

Differentiator

Problem solved

Functional benefit

Brands

  • MINT®: Minimally Invasive Nasal Trabeculostomy - A CE marked device under MDR 2017/745 for glaucoma treatment. Creates five drainage pathways directly within the trabecular meshwork using a mechanical semi-automated trephination with a cutting edge diameter of 0.14mm.
  • MIMS®

Products and services

  • MINT® (Minimally Invasive Nasal Trabeculostomy) MINT® is a stent-free, minimally invasive ophthalmic surgical device that creates five drainage pathways directly within the trabecular meshwork using a proprietary mechanical semi-automated trephination with a 0.14mm cutting edge diameter. It is intended for ophthalmologists and glaucoma surgeons to lower intraocular pressure in open-angle glaucoma patients, either as a standalone procedure or combined with cataract surgery.
  • MIMS® (Minimally Invasive Micro Sclerostomy) MIMS® is a stentless ophthalmic surgical device and system that creates a sclerostomy by inserting a cutting tool into the sclera to remove a small channel of tissue, allowing continuous drainage of fluid to reduce intraocular pressure. The accompanying surgical system features a central control touchscreen and a foot pedal for precise handheld cutting tool movement. It is sold to hospitals and ophthalmologists for standalone glaucoma surgery or combined with cataract surgery.

Quantifiable outcome

  • MINT® 2-year standalone: 97.2% qualified success rate (FDA definition: ≥20% IOP reduction without increasing meds, N=35/36)
  • +3 more outcomes

Companies that use Sanoculis

Customer profile

Named customers4 records

Segments2 records

Ideal customer profiles1 record

Sanoculis technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Sanoculis partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered flagship and core.

  • Bausch + LombflagshipChannel Partner/ Reseller/ Distributor · 25 January 2023Bausch + Lomb invested in Sanoculis during its Series C funding round (January 2023) and entered an exclusive European distribution agreement for Sanoculis' MIMS® glaucoma treatment device. This is a significant strategic partnership providing Sanoculis with broad market access across Europe through a major ophthalmic surgical company. Bausch + Lomb Surgical EMEA is based at 416 Rue Samuel Morse, Le Millenaire 2, BP 1174, 34009 Montpellier, France.
  • SkymedcoreChannel Partner/ Reseller/ DistributorSkymed is the Israeli distributor for Sanoculis products including MIMS® and MINT® devices. Located at Hafrat 2, Yavne, Israel 8122702. Contact: 072-2555-240, service@skymed.co.il. This distribution partnership enables Sanoculis to reach ophthalmologists and eye surgery centers throughout Israel.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Sanoculis competitors and assessment

Company assessment

Direct peers

  • Sight Sciences: Sight Sciences markets the OMNI Surgical System, an ab-interno MIGS device for glaucoma that, like MINT and MIMS, targets interventional glaucoma and combination cataract workflows. Comparable in stage and MIGS focus.
  • Glaukos Corporation: Glaukos is the pioneer and market leader in MIGS, with iStent and iStent inject devices used in standalone and combination cataract-MIGS procedures. Directly competes with Sanoculis' MINT and MIMS in the same ophthalmic surgical channels and target surgeon base.
  • Nova Eye Medical: Nova Eye Medical sells iTrack, a canaloplasty MIGS device for glaucoma. Targets the same MIGS / interventional glaucoma surgeon base with an ab-interno approach, making it a directly comparable peer.
  • New World Medical: New World Medical markets the Kahook Dual Blade, an ab-interno goniotomy device used in standalone and combination cataract-MIGS procedures. Directly competes with Sanoculis in the surgical trabeculostomy space.
  • Ellex Medical Lasers (Lumibird Medical): Ellex (now part of Lumibird Medical) offers laser-based MIGS solutions, including laser trabeculoplasty devices. Targets the same MIGS / interventional glaucoma surgeon base as Sanoculis, though with a different mechanism.

Emerging players

  • iSTAR Medical: iSTAR Medical develops MINIject, a suprachoroidal MIGS implant. Competes in the same MIGS category with a differentiated mechanism, addressing the same glaucoma patient population and surgeon base as Sanoculis.
  • Belkin Vision: Belkin Vision develops the Eagle Direct Selective Laser Trabeculoplasty device, a non-incisional MIGS alternative. Targets the same interventional glaucoma surgeon base with an emerging, non-implant approach.

Regional players

  • MicroSurgical Technology: MicroSurgical Technology (MST) manufactures micro-incision surgical instruments used in ophthalmic surgery, including glaucoma procedures. Comparable as a peer in surgical glaucoma instrumentation, with primary presence in the US.

Broad incumbents

  • Alcon: Alcon is a global ophthalmic surgical incumbent with the Hydrus Microstent (acquired via Ivantis) and a broad cataract surgery portfolio. Overlaps directly with Sanoculis in MIGS and combination cataract-glaucoma procedures, but competes from a much larger installed base and sales footprint.
  • Bausch + Lomb: Bausch + Lomb is both a strategic partner (Series C investor and exclusive European distributor of MIMS) and a broad ophthalmic incumbent with surgical, pharmaceutical, and vision care portfolios. Comparable as a wide-line ophthalmic surgical competitor to Sanoculis' stent-free MIGS offering.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Customer concentration

Sanoculis social profiles

Digital presence

Sanoculis compliance and trust

Trust signal

Compliance2 records

Sanoculis financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Sanoculis leadership team

Management profile

Number of profiles

Profiles7 records

Sanoculis funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Sanoculis M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sanoculis

What does Sanoculis do?

Sanoculis develops and sells two proprietary, stent-free, minimally invasive ophthalmic surgical devices for glaucoma treatment: MINT® (Minimally Invasive Nasal Trabeculostomy) and MIMS® (Minimally Invasive Micro Sclerostomy). Both devices are sold to hospitals, eye surgery centers, and ophthalmologists for standalone use or in combination with cataract surgery, and are CE marked for the European market.

Is Sanoculis a public or private company?

Sanoculis is a private company. It is classified as venture growth investor backed and is currently operating.

When was Sanoculis founded?

Sanoculis was founded in 2012. It employs 1 to 10 people.

Where is Sanoculis based?

Sanoculis is headquartered in Kiryat Gat, Israel, in the Middle East region.

How does Sanoculis make money?

One revenue line is on record: medical Device Sales.

Who are Sanoculis's main competitors?

Direct peers on record are Sight Sciences, Glaukos Corporation, Nova Eye Medical, New World Medical and Ellex Medical Lasers (Lumibird Medical). Emerging players are iSTAR Medical and Belkin Vision. MicroSurgical Technology is listed as a regional player. Broad incumbents are Alcon and Bausch + Lomb.

Does Sanoculis have an API?

No public API is recorded for Sanoculis.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business & FinancialSanoculis Receives CE Mark For MINT® Product For The Treatment Of GlaucomaSanoculis received CE Mark approval for its MINT glaucoma treatment device, which uses a 0.14 mm trephination technology to create openings in the trabecular meshwork. The company cites clinical data showing the device safely lowers intraocular pressure and reduces medication need, and plans a selective commercial pre-launch rollout later this year.PR NewswireEckuity Joins Bausch + Lomb in an Equity Investment in SanoculisEckuity and Bausch + Lomb have made equity investments in Sanoculis, an Israeli medical device company, as part of its Series C funding round. Concurrently, Sanoculis and Bausch + Lomb entered into an exclusive European distribution agreement for Sanoculis' MIMS® glaucoma treatment procedure. This partnership aims to expand Sanoculis' market presence in Europe while allowing Bausch + Lomb to complement its surgical portfolio with a minimally invasive option.PR NewswireBausch + Lomb Announces Second-Quarter 2022 ResultsBausch + Lomb Corporation reported second-quarter 2022 financial results with total revenues of $941 million, a 1% increase year-over-year, while organic revenue grew 6% driven by strong Vision Care and Surgical segment performance. GAAP net income declined significantly to $5 million from $44 million in Q2 2021, primarily due to increased interest expense and foreign exchange headwinds, though the company reaffirmed its full-year 2022 revenue guidance of $3.75–3.80 billion and adjusted EBITDA guidance of $740–780 million. The quarter also saw multiple product launches including XIPERE and Revive contact lenses in the United States, a new drug application submission for NOV03, and strategic agreements with Israeli ophthalmic device startup Sanoculis for glaucoma treatment technology.IFTTTGlaucoma treatment co Sanoculis teams with Bausch + LombSanoculis signed a strategic agreement with Bausch + Lomb, which will distribute MIMS exclusively in Europe and invest in Sanoculis's $14-17 million financing round. The deal gives Sanoculis a $35 million pre-money valuation, and Bausch + Lomb will receive an option to buy the company.PR NewswireBausch + Lomb and Sanoculis Announce Strategic Agreements Designed to Address Unmet Needs in GlaucomaBausch + Lomb Corporation and Sanoculis, an Israeli ophthalmic medical device startup, have entered into strategic agreements including an exclusive European distribution agreement for Sanoculis' MIMS® minimally invasive glaucoma treatment procedure and an equity investment by Bausch + Lomb in Sanoculis as part of a Series C funding round. The agreements also include an option agreement giving Bausch + Lomb the right to purchase all of Sanoculis' assets. MIMS® is CE-marked and offers a stentless surgical approach to glaucoma treatment that creates a sclero-corneal drainage channel during surgery, addressing what the companies describe as an unmet need given the condition's projected rise from 79.6 million cases in 2020 to 111.8 million by 2040.PR NewswireBausch + Lomb and Sanoculis Announce Strategic Agreements Designed to Address Unmet Needs in GlaucomaBausch + Lomb and Sanoculis announced strategic agreements, including an exclusive European distribution deal for Sanoculis' MIMS glaucoma procedure and an equity investment in Sanoculis. The procedure is stentless and CE-marked, and Bausch + Lomb has an option to purchase all of Sanoculis' assets.